| 前收市價 | 0.8500 |
| 開市 | 0.8500 |
| 買盤 | 0.0000 |
| 賣出價 | 0.0000 |
| 拍板 | 2.50 |
| 到期日 | 2024-01-19 |
| 今日波幅 | 0.8500 - 0.8500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2.47k |
- Benzinga
Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal
Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl
- Benzinga
Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate
Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow. The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for a
